Search results
Showing 586 to 600 of 703 results for end of life care
This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes
Evidence-based recommendations on obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults.
Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
Digitally enabled therapies for adults with depression: early value assessment (HTG675)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression.
Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)
Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.
Show all sections
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)
NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .
Guide to the technology appraisal and highly specialised technologies appeal process (PMG41)
This guide outlines the appeal process for the technology appraisal and highly specialised technologies guidance. It sets out the process that NICE follows for appeals and provides guidance for those who wish to make an appeal or who are considering doing so
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.
This guide describes the methods and processes that NICE follows when producing HealthTech guidance. For interventional procedures, this guide covers NICE processes. Methods for interventional procedures guidance are in the NICE's interventional procedures programme manual. The NICE HealthTech programme combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Servo-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children (MIB163)
NICE has developed a medtech innovation briefing (MIB) on Serve-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children .
Evidence-based recommendations on brentuximab vedotin (Adcetris) for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults.